Delaware		77-0454924
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

		Page
Part I: Financial Information		1
Item 1: Financial Statements		1
Unaudited Condensed Consolidated Balance Sheets at September 30, 2002 and March 31, 2002		1
Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2002 and 2001		2
Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2002 and 2001		3
Notes to Unaudited Condensed Consolidated Financial Statements		4
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations		11
Item 3: Quantitative and Qualitative Disclosures About Market Risk		27
Item 4: Controls and Procedures		27
Part II: Other Information		28
Item 1: Legal Proceedings		28
Item 4: Submissions of Matters to a Vote of Security Holders		28
Item 6: Exhibits and Reports on Form 8-K		29
Signatures		30
Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		31
Certification of Chief Executive Officer		31
Certification of Chief Financial Officer		32
Exhibit Index		33

		September 30, 2002				March 31, 2002
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	91,503			$	78,478
Short-term investments			—				13,468
Accounts receivable, net			16,254				17,601
Prepaid expenses and other current assets			1,258				1,327
Total current assets			109,015				110,874
Property and equipment, net			6,826				7,252
Other assets			2,055				1,583
Total assets		$	117,896			$	119,709
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	2,035			$	1,777
Accrued expenses			5,140				9,441
Deferred revenue			11,916				15,617
Total current liabilities			19,091				26,835
Other long-term liabilities			110				130
Total liabilities			19,201				26,965
Commitments and contingency
Stockholders’ equity:
Preferred Stock, $.0001 par value; 5,000,000 shares authorized and no shares issued and outstanding			—				—
Common stock, $.0001 par value; 150,000,000 shares authorized and 30,534,034 and 30,239,786 shares issued and outstanding at September 30, 2002 and March 31, 2002, respectively			3				3
Additional paid-in capital			224,668				223,450
Deferred stock-based compensation			(3,049	)			(7,161	)
Notes receivable from stockholders			(1,997	)			(1,936	)
Accumulated other comprehensive loss			(75	)			—
Accumulated deficit			(120,855	)			(121,612	)
Total stockholders’ equity			98,695				92,744
Total liabilities and stockholders’ equity		$	117,896			$	119,709

		For the Three Months Ended September 30,								For the Six Months Ended September 30,
		2002				2001				2002				2001
Revenue:
Licenses		$	14,690			$	8,205			$	28,067			$	13,574
Services			3,081				1,426				7,827				2,663
Total revenue			17,771				9,631				35,894				16,237
Cost of revenue			3,379				1,878				6,172				3,657
Gross profit			14,392				7,753				29,722				12,580
Operating expenses:
Research and development			4,441				4,308				9,778				8,937
Sales and marketing			6,878				5,574				12,915				10,922
General and administrative			2,105				1,178				4,330				2,705
Amortization of stock-based compensation*			730				1,206				2,631				2,305
Total operating expenses			14,154				12,266				29,654				24,869
Operating income (loss)			238				(4,513	)			68				(12,289	)
Interest income (expense):
Interest income			590				177				1,023				220
Interest expense			(1	)			(42	)			(3	)			(86	)
Interest expense—subordinated convertible promissory notes			—				(526	)			—				(526	)
Interest income (expense), net			589				(391	)			1,020				(392	)
Net income (loss) before income taxes			827				(4,904	)			1,088				(12,681	)
Income taxes			(128	)			(70	)			(331	)			(90	)
Net income (loss)			699				(4,974	)			757				(12,771	)
Less: preferred stock dividend			—				(5,814	)			—				(5,814	)
Net income (loss) attributed to common shareholders		$	699			$	(10,788	)		$	757			$	(18,585	)
Net income (loss) per common share—basic		$	0.02			$	(1.03	)		$	0.03			$	(1.79	)
Net income (loss) per common share—diluted		$	0.02			$	(1.03	)		$	0.02			$	(1.79	)
Pro forma shares outstanding:
Basic			30,182				10,507				30,006				10,380
Diluted			31,900				10,507				32,434				10,380
*    Amortization of stock-based compensation included in expense component:
Cost of revenue		$	19			$	5			$	39			$	15
Research and development			203				290				602				530
Sales and marketing